Figure S2 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Year: 2024
Type: other
Abstract: Drug tolerant residual tumors exhibit variable levels of proliferation and low levels of apoptosis. IHC Quantification and additional IHC results to profile cell proliferation.
Authors: Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu, Lok-Hei Chan, Jungmin Choi, Mary Ann Melnick, Anna Arnal Estape, Zenta Walther, Dejian Zhao, Francesc Lopez-Giraldez, Anna Wurtz, Guoping Cai, Rong Fan, Scott Gettinger, Andrew Xiao, Qin Yan, Robert Homer, Don X. Nguyen, Katerina Politi
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4394817769